Accueil
Détail de l'auteur
Documents disponibles écrits par cet auteur (291)
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Rapport
Contingency management (CM) is a general behavioural intervention technique used in the treatment of drug dependence to systematically arrange consequences and it is designed to weaken drug use and strengthen abstinence. The main elements of CM[...]Rapport
OEDT = EMCDDA ; A. PIRONA ; L. MONTANARI ; I. GIRAUDON ; J. MATIAS ; K. OIEN ; L. VANDAM ; T. SURMONT ; B. GUARITA ; F. MATHIS ; J. MOUNTENEY ; K. NATONIEWSKA ; S. SLEIMAN ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Ad hoc publication | 2021Since early 2020, the COVID-19 pandemic has had a dramatic impact on the way we live, with European countries having to introduce unprecedented measures to protect public health. As with all areas of life, drug consumption, related harms and dru[...]Rapport
OEDT = EMCDDA ; J. FOUNTAIN ; G. BURKHART ; L. MONTANARI | Lisbon : OEDT / EMCDDA | Technical reports | 2017This report provides an overview of the various types of brief interventions (BIs) currently used in European countries in the field of substance use, particularly illicit drugs. Targeted at policymakers and practitioners alike, it covers more t[...]Rapport
This publication provides a practical introduction to the area of quality standards and quality assurance mechanisms and the key steps involved in their implementation in drug services and systems. The primary audience for this guide is those re[...]Rapport
This report provides a summary of the key findings from the assessment of progress of the EU Member States, Norway and Turkey towards the implementation of the revised drug supply indicators, as developed by the EMCDDA in line with the Council c[...]Rapport
OEDT = EMCDDA ; D. HEDRICH ; K. PALCZAK ; K. KEPA ; N. SINGLETON | Lisbon : OEDT / EMCDDA | Manuals | 2021This manual provides a step-by-step guide for those involved in planning and managing infectious diseases and drug services, focusing on how to identify barriers to and opportunities for improving provision of HCV testing and access to treatment[...]Rapport
J. MARSDEN ; A. C. OGBORNE ; M. FARRELL ; RISH B. ; OMS / WHO ; UNDCP ; OEDT = EMCDDA | Genève : OMS / WHO | 2000These guidelines describe methods for the evaluation of treatment services and systems for substance use disorders. The guides are intended to be a companion resource to the WHO/UNDCP/EMCDDA workbook series on the evaluation of costs and effects[...]Rapport
FRANÇAIS : Le présent projet avait pour objectif de rassembler l'information relative aux programmes de formation post-graduée sur les drogues existant en Europe, et d'étudier l'utilité et la faisabilité d'une mise en réseau de ces programmes [...]Rapport
Commission des communautés européennes = Commission of the European communities ; OEDT = EMCDDA | 1993FRANÇAIS : Ce document constitue un recueil de la majorité des textes officiels de la communauté européenne depuis environ vingt ans. Il s'agit d'une des premières publications de l'Observatoire Européen des Drogues dont les objectifs et l'org[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. SEDEFOV ; A. ALMEIDA ; R. CHRISTIE ; P. DUQUE ; A. GALLEGOS ; R. JORGE ; J. DE MORAIS | Lisbon : OEDT / EMCDDA | Risk assessments, ISSN 1725-4493 | 2020This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on [...]Rapport
This paper highlights evidence of legislative activity related to new synthetic drugs as an indicator of Member States’ commitment to the issue. It also examines to what extent legal activity may be attributed to the EU action plan on drugs. Am[...]Rapport
This thematic paper looks at the extent to which legislative attention was paid in the period 2000-2004 to actions considered by Member States to be of high priority at the outset of the strategy and action plan. Over 250 legal texts were analys[...]Rapport
The open sale of cannabis products in Europe has raised concerns among policymakers, both with regard to the legal status of these products and their potential for harm. The products are marketed for their low THC (tetrahydrocannabinol) content,[...]Rapport
OEDT = EMCDDA ; M. P. SCHAUB ; J. Y. C. LEE ; A. PIRONA | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2018This paper presents results from a scoping study on the availability of smartphone-based applications in the drugs field within a European and global context. It explores the range of m-health applications available to users and professionals s[...]Rapport
This paper aims to provide an overview on the development of the evaluation process of the EU Strategy and Action Plan on Drugs. A large part of the initiatives and action impacting on the drug phenomenon are under the direct responsibility of [...]